Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Expedition Growth Capital in connection with investment in Xensam
Mandate

Vinge advises Expedition Growth Capital in connection with investment in Xensam  

February 09, 2024 Employment and Benefits Intellectual Property M&A

Expedition Growth Capital has today announced a $40 million growth investment in the Swedish SaaS company Xensam. Vinge acted as Expedition Growth Capital’s legal advisor in connection with the investment.

Xensam is a provider of an AI-powered Software Assessment Management (SAM) platform. The platform enables its customers to understand how users interact with applications, whether SaaS or on-premise, across the entire digital infrastructure to provide a comprehensive organisational overview across hybrid environments.

Expedition Growth Capital is a London-based growth fund focused on investing in fast-growing companies.

Vinge’s team consisted of Karl Klackenberg, Clara Sohlberg and Johan Gavelin (M&A), Rebecka Målquist (IP), Olivia Onwuta (Employment) and Anna Ekdahl Roos (Transaction Support).

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025